Page 451 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

407
16. ANTHRACYCLINES UTILISEES EN THÉRAPEUTIQUE
KROHN K., Total synthesis of anthracyclinone, Angew. Chem. Int. Ed. Engl., 1986, 25,
790-807.
KROHN K., Synthesis of anthracyclinones by electrophilic and nucleophilic addition to
anthraquinones, Tetrahedron, 1990, 22, 291-318.
HAUSER F. H. et al., Total synthesis of optically active N-benzoyldaunosamine from an
azetidinone, J. Org. Chem., 1994, 49, 2236-2240.
ALLEN J. G. et al., A. powerful o-quinone dimethyde strategy for intermolecular Diels-
Alder cycloadditions, J. Am. Chem. Soc., 2000, 122, 571-575.
Valrubicine, Drugs Future, 1980, 5, 171-172; 1997, 22, 413 ; 1999, 24, 442 ; 2000, 25,
430.
SEKINE A. et al., An enantioselective formai synthesis of 4-demethoxydaunomycin using
the catalytic asymmetric ring opening reaction of meso-epoxide with p-anisidine,
Tetrahedron, 2002, 58, 75-82.
DONNÉES PHARMACOCINÉTIQUES
ALBERTS D. S. et al., The pharmacokinetics of daunomycin in man, Clin. Pharmaco/.
Ther., 1971, 12, 96-104.
ITALIA C. et al., Distribution of 4'epidoxorubicin in human tissues, Br. J. Cancer, 1983,
47, 545-547.
MATSUSHITA Y. et al., A high performance liquid chromatographic method of analysis
of 4'-O-tetrahydropyranyladriamycin and their metabolites in biological samples, J.
Antibiotics, 1983, 880.
DEESEN P. E., LEYLAND-JONES B., Sensitive and specific determination of the new
anthracycline analog 4'-epidoxorubicin and its metabolites by high pressure liquid
chromatrography, Drug Metabolism and Disposition, 1984, 12, 9-13.
IGUCHI H. et al., Pharmacokinectics and disposition of 4'-O-tetrahydropyranyladriamy-
cin in mice by HPLC anaiysis, CancerChemother. Pharmacol., 1985, 15, 132-140.
MAJIMA H., OHTA K., Clinical studies of (2"R)-4'-O-tetrahydropyranyi adriamycin (THP),
Biomed. Pharmacother., 1987, 41, 237-243.
FUMAGALLI L. et al., The pharmacokinetics of liposomai encapsuiated daunorubicin are
not modified by HAART in patients with HIV-associated Kaposi's sarcoma, Cancer
Chemother Pharmacol., 2000, 45, 495-501.
.
VAIDYANATHAN S., BOROUJERDI M., Effect of tamoxifen pretreatment of the pharma-
cokinetics, metabolism and cardiotoxicity of doxorubicin in female rats, Cancer Che-
mother. Pharmacol., 2000, 46, 185-192.
WARREN K. E. et al., Effect of fiuconazole on the pharmacokinetics of doxorubicin in
nonhuman primates, Antimicrob. Agents Chemother., 2000, 44, 1100-1101.
MÉCANISME D'ACTION
BACHUR N.R. et al., A general mechanism for microsomai activation of quinone antican-
cer agents to free radicals, Cancer Res., 1978, 38, 6, 1745-1750.
TRITTON T.R., YEE G., The anticancer agent adriamycin can be actively cytotoxic
without entering cells, Science, 1982, 217, 248-250.
SIMPKINS H. et al., Effects or adriamycin on supercoiled DNA and calf thymus nucleo-
somes studied with fluorescent probes, Cancer Res., 1984, 44, 613-618.